---
title: "Medplus Health Services Ltd (MEDPLUS) — Share Price, Financials & Analysis"
symbol: "MEDPLUS"
company: "Medplus Health Services Ltd"
canonical: "https://tapetide.com/stocks/MEDPLUS"
isin: "INE804L01022"
nse_symbol: "MEDPLUS"
bse_code: "543427"
sector: "Retail"
industry: "Pharmacy Retail"
market_cap_cr: 7872.58
generated_at: "2026-09-13T18:45:16.894Z"
---

# Medplus Health Services Ltd (MEDPLUS)

Canonical page: https://tapetide.com/stocks/MEDPLUS

## Company

- **NSE Symbol:** MEDPLUS
- **BSE Code:** 543427
- **ISIN:** INE804L01022
- **Sector:** Retail
- **Industry:** Pharmacy Retail
- **Macro Sector:** Consumer Discretionary
- **Stock Type:** EQUITY
- **Listed Since:** 2021-12-23
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** medplusindia.com

## Latest Price

- **Price:** ₹660.15
- **Change:** +2.1 (+0.32%)
- **Open:** ₹658
- **Day High:** ₹661.45
- **Day Low:** ₹654
- **Previous Close:** ₹658.05
- **Volume:** 78313
- **As Of:** 2026-09-11T10:01:42+00:00

## Key Fundamentals

Observed at 2026-09-11T04:50:51.289852Z.

- **Market Cap:** ₹7872.58 Cr
- **Classification:** Microcap
- **P/E (reported):** 37.6
- **P/E (TTM):** 37.64
- **EPS (TTM):** ₹17.54
- **EPS (reported):** ₹6.36
- **Book Value:** ₹164.43
- **Price to Book:** 4.01
- **Dividend Yield:** 0%
- **ROE:** 11.12%
- **ROCE:** 12.2%
- **Debt to Equity:** 0.72
- **Revenue (yearly):** ₹6963.8 Cr
- **Net Income:** ₹219.6 Cr
- **EBITDA:** ₹678.7 Cr
- **52-Week High:** ₹1022.2
- **52-Week Low:** ₹648
- **RSI (14):** 40.14

## Tapetide Score

- **Score:** 40 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Fair · Momentum: Falling
- **Percentile:** 14.5 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 39.32 | 9% |
| growth | 59.37 | 9% |
| momentum | 13.51 | 12% |
| ownership | 51.2 | 24% |
| quality | 55.73 | 22% |
| valuation | 50.04 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 28.2% CAGR over last 5 years

### Weaknesses

- Stock is trading at 4.01 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.35% over last 3 years.
- Promoters have pledged 60.7% of their holding.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -8.3% | 244.78% | 191.71% |
| ebitda margin growth | -19.34% | 12.59% | 40.09% | 22.33% |
| net income growth | -48.12% | 46.21% | 66% | 28% |
| revenue growth | 0.76% | 12.6% | 15% | 18% |
| roce | -33.97% | 18.79% | 78.1% | 8.8% |
| roe | -48.15% | 28.85% | 7.97% | 66.47% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1409 | 1441 | 1490 | 1489 | 1576 | 1561 | 1510 | 1543 | 1679 | 1806 | 1864 | 1880 |
| Expenses | 1324 | 1350 | 1385 | 1395 | 1452 | 1429 | 1373 | 1412 | 1530 | 1648 | 1695 | 1746 |
| Operating Profit | 85 | 92 | 106 | 94 | 124 | 133 | 136 | 131 | 149 | 159 | 169 | 133 |
| OPM % | 6 | 6 | 7 | 6 | 8 | 8 | 9 | 8 | 9 | 9 | 9 | 7 |
| Other Income | 10 | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 | 20 |
| Interest | 24 | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 | 33 |
| Depreciation | 55 | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 | 78 |
| Profit before tax | 16 | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 | 42 |
| Tax % | 12 | 31 | -5 | 19 | 19 | 19 | 16 | 20 | 19 | 21 | 20 | 21 |
| Net Profit | 15 | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 | 33 |
| EPS in Rs | 1.22 | 1.15 | 2.79 | 1.2 | 3.24 | 3.83 | 4.29 | 3.54 | 4.63 | 4.82 | 5.33 | 2.76 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2131 | 2273 | 2871 | 3069 | 3779 | 4558 | 5625 | 6136 | 6892 | 7229 |
| Expenses | 2073 | 2153 | 2737 | 2852 | 3507 | 4292 | 5270 | 5648 | 6284 | 6620 |
| Operating Profit | 58 | 120 | 134 | 217 | 273 | 266 | 355 | 488 | 608 | 610 |
| OPM % | 2.7 | 5 | 4.7 | 7 | 7 | 6 | 6 | 8 | 9 | 8 |
| Other Income | 8 | 11 | 17 | 21 | 31 | 46 | 40 | 48 | 71 | 76 |
| Interest | 28 | 50 | 47 | 55 | 66 | 83 | 96 | 103 | 120 | 126 |
| Depreciation | 12 | 59 | 75 | 88 | 119 | 182 | 224 | 250 | 283 | 295 |
| Profit before tax | 26 | 23 | 29 | 95 | 118 | 47 | 73 | 183 | 275 | 264 |
| Tax % | -65 | 48 | 94 | 34 | 20 | -6 | 11 | 18 | 20 | — |
| Net Profit | 42 | 12 | 2 | 63 | 95 | 50 | 66 | 150 | 220 | 210 |
| EPS in Rs | 2080.06 | 585.46 | 107.02 | 1393.11 | 8.03 | 4.17 | 5.48 | 12.56 | 18.3 | 17.54 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 148 | 303 | 291 | 528 | 730 | 1394 | 1467 | 1554 | 1717 | 1951 |
| Borrowings | 204 | 162 | 429 | 477 | 590 | 815 | 900 | 1010 | 1120 | 1424 |
| Other Liabilities | 183 | 179 | 239 | 344 | 245 | 361 | 406 | 417 | 500 | 533 |
| Total Liabilities | 535 | 644 | 959 | 1349 | 1566 | 2594 | 2797 | 3005 | 3360 | 3933 |
| Fixed Assets | 81 | 83 | 377 | 419 | 517 | 799 | 1138 | 1242 | 1296 | 1595 |
| CWIP | 2 | 1 | 1 | 5 | 6 | 20 | 25 | 11 | 16 | 32 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 453 | 560 | 580 | 924 | 1043 | 1775 | 1633 | 1752 | 2047 | 2306 |
| Total Assets | 535 | 644 | 959 | 1349 | 1566 | 2594 | 2797 | 3005 | 3360 | 3933 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 34 | 32 | 147 | -7 | 3 | 170 | 90 | 144 | 540 | 496 |
| Cash from Investing Activity | -15 | -18 | -19 | -28 | -35 | -703 | 429 | -83 | -318 | -128 |
| Cash from Financing Activity | -29 | -1 | -83 | 90 | -6 | 440 | -170 | -198 | -228 | -256 |
| Net Cash Flow | -10 | 14 | 45 | 56 | -37 | -93 | 350 | -137 | -5 | 112 |
| Free Cash Flow | 19 | 32 | 125 | -37 | -51 | 56 | -78 | 61 | 482 | 373 |
| CFO/OP | 70 | 96 | 133 | 6 | 15 | 75 | 39 | 49 | 120 | 94 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Inventory Days | 76 | 76 | 78 | 101 | 113 | 112 | 117 | 111 | 106 | 99 |
| Days Payable | 25 | 27 | 31 | 37 | 22 | 30 | 27 | 21 | 24 | 22 |
| Cash Conversion Cycle | 51 | 51 | 48 | 65 | 91 | 82 | 91 | 92 | 83 | 79 |
| Working Capital Days | 14 | 13 | 8 | 25 | 46 | 100 | 58 | 58 | 54 | 49 |
| ROCE % | 19 | 13 | 12 | 9 | 13 | 10 | 5 | 7 | 10 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 40.41% | 40.45% | 40.39% | 40.39% | 40.39% | 40.39% | 40.34% | 40.32% | 40.29% | 40.29% | 40.22% | 40.19% |
| FIIs | 12.36% | 12.96% | 14.94% | 14.85% | 14.72% | 15.23% | 15.61% | 16.42% | 16.54% | 16.83% | 15.53% | 14.38% |
| DIIs | 25.49% | 16.28% | 22.47% | 22.17% | 27.97% | 25.65% | 26.19% | 26.04% | 26.52% | 26.57% | 27.82% | 29.95% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 6.4% | 6.15% | 7.3% | 7.56% | 11.84% | 13.21% | 13.1% | 12.59% | 12.22% | 11.88% | 11.82% | 10.9% |
| Others | 15.33% | 24.16% | 14.9% | 15.03% | 5.07% | 5.52% | 4.77% | 4.64% | 4.43% | 4.42% | 4.62% | 4.58% |
| No. of Shareholders | 66430 | 66048 | 74976 | 76934 | 87328 | 83912 | 83439 | 81742 | 78337 | 79157 | 77278 | 76005 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 665.35 | Sell |
| EMA (10) | 665.8 | Sell |
| SMA (20) | 669.08 | Sell |
| EMA (20) | 673.27 | Sell |
| SMA (50) | 713 | Sell |
| EMA (50) | 711.64 | Sell |
| SMA (100) | 793.39 | Sell |
| EMA (100) | 756.46 | Sell |
| SMA (200) | 810.88 | Sell |
| EMA (200) | 789.49 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.12 | Neutral |
| MACD (12,26,9) | -13.02 | Buy |
| Stochastic (14,3,3) | 31.31 | Neutral |
| ADX (14) | 24.85 | Neutral |
| Williams %R (14) | -74.15 | Neutral |
| ATR (14) | 18.41 | Neutral |
| ROC (12) | -4.62 | Sell |
| Stoch RSI (14) | 42.47 | Neutral |
| UO (7,14,28) | 50.35 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 7 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 7 analyst ratings, observed at 2026-09-11T04:50:49.642868+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Board Meeting Outcome for Outcome Of Board Meeting Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83a7167a-424a-46f1-be54-b39dbf144700.pdf) |
| 2026-09-10 | [Board Comments On Fine Levied By The Exchange](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d8c4c869-f638-4331-a044-ad1ac6abbc50.pdf) |
| 2026-08-26 | [Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=C8F9B181_3E44_428E_BEEE_46DB3D4A8617_164152.pdf) |
| 2026-08-26 | [Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D3E604C1_296B_47A3_834B_D60363EB96DC_164412.pdf) |
| 2026-08-21 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D0D4D960_2EFB_43CE_A32E_99129E464005_161957.pdf) |
| 2026-08-21 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=622EE92B_80A5_42A3_96F1_4D837425A088_180515.pdf) |
| 2026-08-18 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=062f6bf5-69c9-4ab5-aa78-cd066c340f29.pdf) |
| 2026-08-17 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db815c1c-d4b0-424a-858f-e1e0a9383a56.pdf) |
| 2026-08-06 | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7927d162-cfac-4d05-b066-d2abd054f34f.pdf) |
| 2026-08-05 | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=006a6278-00ae-4412-a114-3de8b275f6d4.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7fa238dc-f04b-49f8-9f97-dda7555c5bb2.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=702a6bf0-a772-4dff-b333-642c07b9b22c.pdf) |
| 2026-02-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7146c0a-13f1-4878-b869-9cbeba250aff.pdf) |
| 2025-11-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55fe0b41-b49e-4068-b289-e5a25fb687e3.pdf) |
| 2025-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1df9138-fb8e-48ca-9cba-5a5d49246ea8.pdf) |
| 2025-05-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=242dec76-e2c1-4907-a8a4-edf44129217d.pdf) |
| 2024-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93b2707e-84fa-4f1a-aae5-7c5077e2020e.pdf) |
| 2024-08-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8d150c0-a062-4dd9-9f35-c02cdd92ac26.pdf) |
| 2024-05-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f442a949-dc48-44a0-b936-5e3913a56e69.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-21 | [Outcome Of Board Meeting Under SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 (Listing Regulations)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6dec2715-d99d-4f58-af74-5d6eb02d84fd.pdf) |
| 2026-05-20 | [Financial Results For Quarter And Year Ended On March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e263566-ff1c-4396-872c-6b616cbc23b1.pdf) |
| 2026-01-30 | [Board Meeting Outcome For Un-Audited Financial Results Of The Company For The Quarter Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=24096aa3-b9db-4a46-b8e7-20fd91e0d8be.pdf) |
| 2025-10-31 | [Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17721a4a-2f0f-484c-b23c-55ace2a002d4.pdf) |
| 2025-08-02 | [Un-Audited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3eb9cc53-54f4-4e87-a9f5-68d0d069c0a8.pdf) |
| 2025-05-27 | [Audited Financial Results For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfc0f4a2-f64b-4dec-91fd-fec474fb914d.pdf) |
| 2025-01-31 | [Meeting Held On January 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec196777-c83f-44a7-93b9-f82238b3ab09.pdf) |
| 2024-11-12 | [Outcome Of The Board Meeting Held On November 12, 2024 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17529be7-a01a-4139-af40-06e8f8b4a176.pdf) |
| 2024-08-02 | [Outcome Of The Board Meeting Held On August 2, 2024 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a2daa62-5449-4410-a838-b7aea1627795.pdf) |
| 2024-06-05 | [Results - Financial Results May 28, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=24b86cce-c6ec-47c0-93ed-e8861afa2646.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09b5c9a6-0b3c-404d-b2e2-9aed32246d4e.pdf) |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cbe99f3-eb2c-40b8-b700-98981fe4ee64.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2aafe5f2-3cd6-4109-bfce-981d7dd97aef.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ccd87e41-b767-4df0-bd3a-34172b6b7657.pdf) |
| 2025-10-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7da27c8e-88be-4144-93c4-1325038fd387.pdf) |
| 2025-08-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a66676d1-1a3f-4856-a0dc-e53f62e71b71.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=163a824f-18b3-4837-bf4b-90e440ca7de6.pdf) |
| 2025-01-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0872b669-0345-497f-9bc2-0132c8b557ba.pdf) |
| 2024-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c608a65b-8936-45db-a7bf-676ddc7e4aba.pdf) |
| 2024-08-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ec1ac0b-8d24-46bb-9bb7-2cdd3ec15fb2.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Two MedPlus subsidiary stores face 7-day and 2-day drug license suspensions; potential revenue loss Rs 1.25 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Two MedPlus subsidiary stores face 7-day and 2-day drug license suspensions; potential revenue loss Rs 1.25 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5835be15-1705-47f1-8080-e576e2aa2c04.pdf) |
| 9h - Subsidiary Optival received five-day drug license suspension for one Karnataka store; potential revenue loss Rs 5.39 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Subsidiary Optival received five-day drug license suspension for one Karnataka store; potential revenue loss Rs 5.39 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a4121938-e6d5-4f2a-b1f4-a8cda8968abd.pdf) |
| 9h - Optival subsidiary received three-day drug license suspension for Mandya store; order dated 21-Mar-2026; potential revenue loss Rs0.37 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Optival subsidiary received three-day drug license suspension for Mandya store; order dated 21-Mar-2026; potential revenue loss Rs0.37 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8f94bff7-81dd-4aff-bb31-1dbccc6944d6.pdf) |
| 9h - Optival subsidiary received one-day drug license suspension for a Delhi store; potential revenue loss Rs 0.30 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Optival subsidiary received one-day drug license suspension for a Delhi store; potential revenue loss Rs 0.30 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/37884d5e-b036-481c-8595-fb1c52679ad9.pdf) |
| 9h - Earnings call for Q4 and FY26 results scheduled on May 21, 2026 at 16:00 IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9h - Earnings call for Q4 and FY26 results scheduled on May 21, 2026 at 16:00 IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/07ea21c0-3996-452d-9f30-06ebdec1204e.pdf) |
| 9 Apr - Telangana store drug license suspended for two days; potential revenue loss Rs 0.28 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9 Apr - Telangana store drug license suspended for two days; potential revenue loss Rs 0.28 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2d77837f-aee6-45af-abb8-174d5d9f741c.pdf) |
| 7 May - Optival subsidiary’s Nashik store drug license suspended for five days; potential revenue loss Rs 0.75 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 7 May - Optival subsidiary’s Nashik store drug license suspended for five days; potential revenue loss Rs 0.75 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8fd7c52d-7c0c-4c21-a3d9-522690231f34.pdf) |
| 6 May - Subsidiary’s Chhattisgarh store drug licence suspended for 65 days; potential revenue loss Rs 16 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 6 May - Subsidiary’s Chhattisgarh store drug licence suspended for 65 days; potential revenue loss Rs 16 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c7f0be86-de21-4d96-a5cb-15b5e244c6a0.pdf) |
| 4 Mar - Optival subsidiary store in Sangvi, Pune suspended drug license seven days; order received 03.03.2026; potential revenue loss Rs 3.85 lacs. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 4 Mar - Optival subsidiary store in Sangvi, Pune suspended drug license seven days; order received 03.03.2026; potential revenue loss Rs 3.85 lacs.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43f61af0-c7e0-4ebc-9830-a0446721bb66.pdf) |
| 3 May - Board meets May 20, 2026 to approve FY26 audited standalone and consolidated results; trading window closed till May 22. | [Update on board meeting 3 May - Board meets May 20, 2026 to approve FY26 audited standalone and consolidated results; trading window closed till May 22.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2a6748e4-9c1f-434c-b717-5af2edb359c3.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17d3948b-8f61-48be-a44f-25844f4de67f.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17d3948b-8f61-48be-a44f-25844f4de67f.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/MEDPLUS_16112024174113_EarningcalltranscriptQ2FY25.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1c632aaf-471a-4c9f-964b-605bef4513c8.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/1c632aaf-471a-4c9f-964b-605bef4513c8.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2aafe5f2-3cd6-4109-bfce-981d7dd97aef.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2aafe5f2-3cd6-4109-bfce-981d7dd97aef.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f11c0560-be9f-4f39-ad68-575342c7ac00.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f11c0560-be9f-4f39-ad68-575342c7ac00.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c935bd94-16a3-41b0-94b4-0c760a24d32e.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8b105d53-41b8-4a8d-bd2f-f906c1432ee9.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/32177362-6f26-4804-901a-f49bc8e163c9.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:45:16.894Z.